Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12182/20200360606 http://scihub22266oqcxt.onion/10.12182/20200360606 32220179!ä!32220179 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Sichuan+Da+Xue+Xue+Bao+Yi+Xue+Ban 2020 ; 51 (2): 146-150 Nephropedia Template TP {{tp|p=32220179|t=2020. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19 |pdf=|usr=}}{{32220179}} gab.com Text The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19 JO: Sichuan Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32220179 #FOAvip Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients. Twit Text FOAVip The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19 ????Sichuan Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32220179 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32220179 #FOAvip English Wikipedia <ref>{{Cite pmid|32220179}}</ref> The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19 #MMPMID32220179 Ma WX; Ran XW Sichuan Da Xue Xue Bao Yi Xue Ban 2020[Mar]; 51 (2): 146-150 PMID32220179show ga Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients. |*Betacoronavirus[MESH] |*Blood Glucose/drug effects/metabolism[MESH] |Adult[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications[MESH] |Diabetes Mellitus, Type 2/complications/*drug therapy[MESH] |Diabetic Ketoacidosis/etiology/prevention & control[MESH] |Humans[MESH] |Hyperglycemia/drug therapy[MESH] |Hyperglycemic Hyperosmolar Nonketotic Coma/etiology/prevention & control[MESH] |Hypoglycemic Agents/*therapeutic use[MESH] |Insulin/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications[MESH] The Management of Blood Glucose Should be Emphasized in the Treatment(epmc).pdf DeepDyve Pubget Overpricing